ZA201403302B - Method for inhibition of deubiquitinating acttivity - Google Patents

Method for inhibition of deubiquitinating acttivity

Info

Publication number
ZA201403302B
ZA201403302B ZA2014/03302A ZA201403302A ZA201403302B ZA 201403302 B ZA201403302 B ZA 201403302B ZA 2014/03302 A ZA2014/03302 A ZA 2014/03302A ZA 201403302 A ZA201403302 A ZA 201403302A ZA 201403302 B ZA201403302 B ZA 201403302B
Authority
ZA
South Africa
Prior art keywords
acttivity
deubiquitinating
inhibition
deubiquitinating acttivity
Prior art date
Application number
ZA2014/03302A
Other languages
English (en)
Inventor
Stig Linder
Rolf Larsson
Original Assignee
Vivolux Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivolux Ab filed Critical Vivolux Ab
Publication of ZA201403302B publication Critical patent/ZA201403302B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2014/03302A 2011-10-19 2014-05-08 Method for inhibition of deubiquitinating acttivity ZA201403302B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1100776 2011-10-19
SE1200303 2012-05-16
PCT/SE2012/000158 WO2013058691A1 (en) 2011-10-19 2012-10-15 Method for inhibition of deubiquitinating activity

Publications (1)

Publication Number Publication Date
ZA201403302B true ZA201403302B (en) 2015-05-27

Family

ID=48141165

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/03302A ZA201403302B (en) 2011-10-19 2014-05-08 Method for inhibition of deubiquitinating acttivity

Country Status (21)

Country Link
US (1) US9221761B2 (enExample)
EP (1) EP2780326B1 (enExample)
JP (1) JP6165748B2 (enExample)
KR (1) KR102022575B1 (enExample)
CN (1) CN104271557B (enExample)
AU (1) AU2012326682B2 (enExample)
BR (1) BR112014009365B1 (enExample)
CA (1) CA2852518C (enExample)
CL (1) CL2014000998A1 (enExample)
DK (1) DK2780326T3 (enExample)
EA (1) EA026409B1 (enExample)
ES (1) ES2713484T3 (enExample)
HU (1) HUE041816T2 (enExample)
IL (1) IL232118A (enExample)
MX (1) MX345467B (enExample)
MY (1) MY169330A (enExample)
PL (1) PL2780326T3 (enExample)
PT (1) PT2780326T (enExample)
SG (1) SG11201401608PA (enExample)
WO (1) WO2013058691A1 (enExample)
ZA (1) ZA201403302B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041816T2 (hu) * 2011-10-19 2019-05-28 Vivolux Ab Módszer deubikitinációs aktivitás gátlására
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
WO2016004221A1 (en) * 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
LT3277677T (lt) * 2015-03-30 2021-05-25 Mission Therapeutics Limited 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai
CN106146542A (zh) * 2015-04-23 2016-11-23 北京大学 姜黄素硼酸衍生物,其制备方法和应用
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
US10416163B2 (en) * 2016-02-26 2019-09-17 Regents Of The University Of Minnesota Method and treatment of recurring endometrial cancer with an inhibitor of USP14
SG11201907844TA (en) * 2017-01-30 2019-09-27 Up Therapeutics Inc Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
CN111956804B (zh) * 2020-07-21 2022-01-07 广州医科大学 Otub1的抑制剂的新应用
CN114959036A (zh) * 2022-06-07 2022-08-30 北京大学 Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779230C (en) * 1999-12-03 2006-05-25 Emory University Curcumin analogues for treating cancer
JP2005529080A (ja) * 2002-03-08 2005-09-29 エモリー ユニバーシティ 腫瘍の増殖および脈管形成のサプレッサとしての新規のクルクミノイド−第VIIa因子構築物
WO2007007207A2 (en) * 2005-04-13 2007-01-18 Khairia Youssef Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
EP1749822B1 (en) * 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
JP2009516656A (ja) * 2005-11-22 2009-04-23 ユニバーシティ オブ サスカチュワン 抗腫瘍活性化合物
US20120316203A1 (en) * 2009-07-06 2012-12-13 The Ohio State University Research Foundation Compositions and Methods for Inhibition of Cancers
HUE041816T2 (hu) * 2011-10-19 2019-05-28 Vivolux Ab Módszer deubikitinációs aktivitás gátlására

Also Published As

Publication number Publication date
EA201490800A1 (ru) 2014-09-30
HK1203194A1 (en) 2015-10-23
DK2780326T3 (en) 2019-03-04
CN104271557B (zh) 2017-12-05
CN104271557A (zh) 2015-01-07
ES2713484T3 (es) 2019-05-22
JP2014530852A (ja) 2014-11-20
EP2780326A1 (en) 2014-09-24
AU2012326682B2 (en) 2016-02-18
EA026409B1 (ru) 2017-04-28
CL2014000998A1 (es) 2014-10-10
NZ624019A (en) 2016-07-29
SG11201401608PA (en) 2014-07-30
PT2780326T (pt) 2019-03-04
IL232118A (en) 2016-06-30
US9221761B2 (en) 2015-12-29
WO2013058691A1 (en) 2013-04-25
BR112014009365B1 (pt) 2021-08-03
CA2852518C (en) 2019-09-24
KR102022575B1 (ko) 2019-09-18
CA2852518A1 (en) 2013-04-25
MY169330A (en) 2019-03-21
EP2780326B1 (en) 2018-12-26
BR112014009365A2 (pt) 2017-04-18
PL2780326T3 (pl) 2019-06-28
MX345467B (es) 2017-02-01
HUE041816T2 (hu) 2019-05-28
AU2012326682A1 (en) 2014-05-01
EP2780326A4 (en) 2015-04-22
US20140228354A1 (en) 2014-08-14
KR20140078742A (ko) 2014-06-25
IL232118A0 (en) 2014-05-28
JP6165748B2 (ja) 2017-07-19
MX2014004646A (es) 2014-08-01

Similar Documents

Publication Publication Date Title
ZA201305971B (en) Method for the purification of biphephos
GB201110095D0 (en) Method of treatment
EP2773754A4 (en) Methods of Treatment
ZA201305972B (en) Method for the preparation of biphephos
HRP20260473T1 (hr) Metoda generiranja rekonstruiranog bloka
PL3829175T3 (pl) Sposób konstruowania listy scalania
IL227593A (en) A method for making noribogain from Wakanjin and purifying it
IL232118A0 (en) A method to inhibit de-ubiquitin activity
HUE037086T2 (hu) Eljárás alanin aerob elõállítására
ZA201209370B (en) Method for manufacturing of quinoline-3-carboxamides
PT2784056T (pt) Método para a produção seletiva de n-metil-para-anisidina
IL228913A0 (en) A method for cleaning Mitzfungin
EP2758780A4 (en) METHOD OF TREATING MULTIPLE SCLEROSIS
IL228073A0 (en) Method for the determination of polysorbate
GB201408437D0 (en) Method for inhibiting the plugging of conduits by gas hydrants
EP2668260A4 (en) METHOD FOR MODIFYING BACTERIA
ZA201302573B (en) Method for purification of complement factor h
EP2743258A4 (en) PROCESS FOR PURIFYING LEVO-OXIRACETAM
GB201105407D0 (en) Purification method
HUE038149T2 (hu) Eljárás acél kezelésére
EP2780475A4 (en) PROCESS FOR ALL-PECIFIC AMPLIFICATION
GB201102475D0 (en) Method of reducing offset
GB201119607D0 (en) Method of manufacture
EP2791324A4 (en) PROCESSING METHOD
PL396148A1 (pl) Sposób utylizacji szlamu z lugu zielonego